DPHARMA 7148 DUOPHARMA BIOTECH BERHAD | Revenue and Profit Record High (Q1FY2023)
The pharmaceutical industry plays a crucial role as an integral part of the global healthcare system. With the increasing global population and longer life expectancy, the demand for medications is also on the rise. Particularly in developing countries, improvements in healthcare standards and an aging population are driving the demand and reliance on pharmaceuticals. According to a survey conducted by the Pharmaceutical Association of Malaysia (PhAMA), the pharmaceutical industry contributed RM6.00 billion to Malaysia's Gross Domestic Product (GDP), and it is expected to contribute another RM10.00 billion by 2024.
A few days ago, Duopharma Biotech Berhad (DPHARMA, 7148), a renowned Malaysian pharmaceutical company, announced impressive performance results with record-high revenue and profit for the first quarter.
As a reference, DPHARMA is a pharmaceutical company equipped with advanced medical technology. It was established in 1978 and went public in 2002. The company operates three research and manufacturing facilities in the Klang Valley of Malaysia, located in Bangi, Klang, and Glenmarie, Shah Alam. Additionally, DPHARMA has subsidiaries in Singapore, the Philippines, and Indonesia. Not to mention that the company also collaborates with the Indian pharmaceutical company Biocon Limited.
DPHARMA's main business involves the research, development, and manufacturing of generic drugs and healthcare products, which are then sold to private and government healthcare centres. Based on the 2022 annual report, approximately 57.29% of the revenue comes from private healthcare centres, while the remaining 42.71% comes from government or public healthcare centres. The company has a broad market presence and has exported its products to 31 countries. However, Malaysia remains DPHARMA's primary sales market, accounting for approximately 93.99% of the revenue in the fiscal year 2022.
Now, let's delve into the latest performance announced by DPHARMA for Q1FY2023.
Revenue Comparison (YoY +7.81%, QoQ +31.92%)
As of March 31, 2023, the company achieved approximately RM200.47 million in revenue, representing an increase of approximately RM14.54 million or 7.81% compared to the same period last year, when revenue was RM185.94 million. This growth is primarily attributed to an increase in sales volume of prescription drugs.
Out of the RM200.47 million revenue, approximately RM188.73 million came from Malaysian customers, while the remaining RM11.74 million came from overseas sales.
Compared to the previous quarter, the company's revenue significantly rose by approximately RM48.52 million or 31.92%, primarily driven by increased demand for medications from the Ministry of Health. It is worth noting that the previous quarter (4QFY22) usually experiences lower purchases from the Ministry of Health due to the year-end accounting period. Therefore, the orders from the Ministry of Health witnessed a significant increase this quarter.
Net Profit Comparison (YoY +11.53%, QoQ +31.87%)
Driven by the overall robust revenue performance, DPHARMA achieved a net profit of approximately RM22.63 million this quarter, representing a year-on-year and quarter-on-quarter growth of approximately 11.53% and 31.87%, respectively.
However, the increase in electricity costs and labor expenses has affected the company's profitability to some extent. It is anticipated that the company may offset the rising operating costs by increasing product selling prices in the future.
Outlook
The company is poised to benefit from patients returning to hospitals, increased government allocations to the Ministry of Health, and a gradual stabilization of active pharmaceutical ingredient prices. Additionally, DPHARMA's introduction of pure plant-based healthcare products such as Champs and Flavettes will be advantageous for the company's future profit growth.
It is worth mentioning that the company currently holds a three-year contract valued at RM375.00 million, which involves supplying reconstituted insulin formulations (Insugen-Insulin Recombinant Human Formulations) to the Ministry of Health until April 2025. Furthermore, the contracts with government hospitals and clinics for the supply of both pharmaceutical and non-pharmaceutical products have been extended until June 30, 2023.
In addition, Malaysia plans to open five public hospitals and 19 private hospitals in the next three years, further enhancing the company's growth potential.
Given the high growth potential and the current price-to-earnings ratio (P/E) of 19.52 times, what are your thoughts on DPHARMA?
#DPHARMA
https://xifu.my/OpinionsComment.aspx?BID=B02436230PBAA0EC
Singapore Investment Bloggers
-
-
-
-
-
-
-
-
-
SBJUL23 GX23070H is 2.82%3 hours ago
-
-
-
-
May 2023 Portfolio6 hours ago
-
Retirement Journey Update for May 20237 hours ago
-
-
-
-
Sea Limited – Dip or Doom?11 hours ago
-
-
-
-
-
-
Dividends for May 20231 day ago
-
-
-
-
Investment Summary - May 20231 day ago
-
-
-
-
-
-
Support Us: Learn To Invest1 day ago
-
-
Portfolio (May 31st, 2023)1 day ago
-
-
-
-
-
Looking at Rental Yields2 days ago
-
-
-
-
-
-
-
-
-
Month of May 20232 days ago
-
-
-
I was right! Sort of....2 days ago
-
-
-
Updates for May 20233 days ago
-
-
-
-
-
-
-
-
-
-
-
Dirty, Dirty Coal6 days ago
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Meta's new Twitter competitor1 week ago
-
Liquidity, Liquidity, Liquidity1 week ago
-
-
-
-
-
-
-
-
-
-
Success in life2 weeks ago
-
-
Eh Aye…2 weeks ago
-
Welcome Rain!2 weeks ago
-
-
-
-
A New Light3 weeks ago
-
-
-
-
$250 to 5mil3 weeks ago
-
-
-
-
-
-
Monthly Summary of April 20234 weeks ago
-
-
-
-
-
-
My retirement test drive: Q1, 20231 month ago
-
Snack Empire – Crunch Time1 month ago
-
祭友文:拿起来,再放下1 month ago
-
-
-
-
-
The Ben Mezrich Screenplay Token1 month ago
-
-
-
1Q 2023 Investment Strategy Update1 month ago
-
-
-
Dividends Contributors – Top 102 months ago
-
-
Individual Income Tax Season 2023 Singapore2 months ago
-
-
-
How long is the RES course?2 months ago
-
Cost of having a baby2 months ago
-
-
-
I don’t know how My Portfolio is Performing2 months ago
-
-
-
-
-
-
How to become a real estate agent in Singapore3 months ago
-
-
New Launch Spotlight: The Botany at Dairy Farm4 months ago
-
A New Beginning – The Year of the Rabbit4 months ago
-
-
-
Demoralized4 months ago
-
2022 Thoughts, Hello 2023!5 months ago
-
-
Series of Defaults for Maple Finance5 months ago
-
Takeaways from “Sea Change”5 months ago
-
-
Greed is Coming Back6 months ago
-
-
-
-
Investing is Easy6 months ago
-
-
-
-
-
-
-
-
-
Portfolio Update - 2Q202210 months ago
-
-
What is Overemployment11 months ago
-
Terra Hill Condo (former Flynn Park)11 months ago
-
Alibaba VS Tencent: The Battle Royale11 months ago
-
-
-
-
-
-
-
-
-
Recent Post
-
-
-
-
-
RCECAP 9296 RCE CAPITAL BERHAD 改变派息政策1 week ago
-
-
二小姐《无情的人儿》2 weeks ago
-
-
-
-
-
-
-
下跌股:康大工业(KOTRA,0002, 主板保健股) RM5.57支撑4 months ago
-
-
【马股】16%+高息股!0负债高现金!能入吗?6 months ago
-
8月棕油库存料升13.5% 种植公司次季净利看涨9 months ago
-
CHINWEL – Not too late to invest.11 months ago
-
恒大置地(TAMBUN,5191,主板产业股)迈向98仙/敏源1 year ago
-
-